RxDoctor Payments Data

Brian Cross, MD

Internal Medicine · Griffin, GANPI 1720082613

Payments from drug & device makers

$5,608in general payments, 2019–2025

Across 370 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$905
  • AstraZeneca$686
  • Pfizer$543
  • Astellas Pharma US Inc$409
  • Lilly USA, LLC$375
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$300
  • plus $2K from 40 others

What the payments were for

  • Food & beverage$5,590100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,608 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$66,157
Medicare patients
238
Services billed
1,151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin152$143,796
FarxigaDapagliflozin Propanediol118$124,717
OzempicSemaglutide92$123,584
Stiolto RespimatTiotropium Br/Olodaterol Hcl194$107,631
MounjaroTirzepatide67$92,728
TrulicityDulaglutide73$89,302
EliquisApixaban98$87,409
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$73,470
RybelsusSemaglutide32$58,243
JanuviaSitagliptin Phosphate57$51,748
Bydureon BciseExenatide Microspheres48$49,309
BiktarvyBictegrav/Emtricit/Tenofov Ala12$47,775
Repatha SureclickEvolocumab58$46,399
XareltoRivaroxaban42$34,903
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$30,693

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Tradjenta, Combivent Respimat$148$273,463372 claims
Lilly USA, LLCMounjaro, Trulicity$375$182,030140 claims
Novo NordiskOzempic, Rybelsus$222$181,828124 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$686$167,305187 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$46$116,274155 claims
PfizerEliquis$543$87,40998 claims
MerckJanuvia, Janumet$89$62,85068 claims
Johnson & JohnsonXarelto$128$34,90342 claims
Astellas Pharma US IncMyrbetriq$409$26,25641 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$32$24,48820 claims
AbbVieLinzess, Synthroid$138$20,178117 claims
AmgenProlia$905$18,97111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Griffin

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →